Health ❯ Healthcare ❯ Patient Safety

Adverse Events

Device Malfunction Monitoring and Investigation Medical Interventions Monitoring Major Bleeding Device Malfunctions Injury Reporting Self-Administration Risks Hematologic Toxicity Clinical Investigations Medication Complications Clinical Research Ethics Clinical Protocols Serious Adverse Events Clinical Trials Reporting Complications Surveillance Systems Clinical Safety Drug Dosage Effects Injury and Death Long-term Studies Vaccination Guidelines Gastrointestinal Events Hypoglycemia Systemic Failures Clinical Data Requirements Clinical Outcomes Overdose Risks Gastrointestinal Adverse Events Acute Liver Injury Gastrointestinal Symptoms Safety Profiles Drug Efficacy Liver Failure Surgical Interventions Reporting Mechanisms Data Monitoring Committees Fatalities Linked to Medications Treatment Tolerability Monitoring Systems Injuries and Deaths Medication Errors Tolerability Profiles Reporting Obligations

Structure’s Oral Obesity Pill Delivers 16.3% Placebo-Adjusted Weight Loss in Phase 2

The company set an FDA end-of-Phase-2 meeting for Q2 2026 ahead of a planned Phase 3 start in the second half of the year.

FDA Rejects Regenxbio’s Hunter Syndrome Gene Therapy Application

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

FDA Issues Early Alert on Certain FreeStyle Libre 3 Sensors After False Low Readings Linked to Harm

Protara Reports Strong Interim Phase 2 Results for TARA-002 in Pediatric Lymphatic Malformations

FDA Issues Safety Alert on RF Microneedling Injuries

Low-Dose Transplant Drug Preserves Beta Cells in Young People With Type 1 Diabetes, Phase 2 Trial Finds

Capsida Halts STXBP1 Gene Therapy Trial After First Pediatric Participant Dies

Iza-Bren Plus Osimertinib Delivers 100% Response in Small First-Line EGFR-Mutant NSCLC Cohort

ESC Trials Recast Antiplatelet Strategies After PCI and CABG

Tandem Diabetes Announces Urgent Medical Device Correction for t:slim X2 Pumps

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

Sarepta Halts Elevidys Shipments for Non-Ambulatory Patients After Second Fatal Liver Failure

FDA Halts Rocket’s RP-A501 Gene Therapy for Danon Disease After Patient’s Death